Suspect varicella cases
• Consider varicella in patients of any age or vaccination status who have symptoms compatible with varicella. (See CDPH Varicella Quicksheet in "Resources")

Varicella case definition
• An illness with acute onset of diffuse (generalized) maculo-papulovesicular rash without other apparent cause. In vaccinated persons, varicella that develops more than 42 days after vaccination (breakthrough disease) due to infection with wild-type VZV is usually mild, with fewer than 50 skin lesions and of shorter duration of illness. The rash may also be atypical in appearance (maculopapular with few or no vesicles).

Varicella infectious period
From 1 to 2 days before rash until all the lesions are crusted (usually about 5 days).

Prevent healthcare exposures
• Ensure that your facility has protocols in place to:
  o Train telephone triage staff to identify patients with symptoms of varicella, and schedule suspect cases who need care at the end of the day when other patients aren’t present, if possible; and
  o Promptly identify suspect varicella cases arriving at the facility who have not called ahead.
• Ensure that all staff have documentation of immunity to varicella.

Infection control measures for suspected varicella patients
1. Do not allow patient to stay in the waiting area.
2. Immediately place a surgical mask on patient suspected to have varicella and place patient in airborne infection isolation room (AIIR), if one is available.
3. The patient may remove their mask only when in an AIIR with the door closed.
4. If an AIIR is not available, place patient in a single person exam room with a closed door OR evaluate patient in an outside location away from other patients.
5. Only essential visitors and staff should be in the patient room. All staff should use an N95 or PAPR along with standard and contact precautions (gowns, gloves, and use of hand hygiene at all times).
6. Staff known to be susceptible to varicella should not enter the room.
7. If patient’s symptoms are clinically compatible with varicella, diagnosis can be made on clinical grounds, but if there is a question about diagnosis, laboratory testing can be done (see below).
8. If possible, keep exam room vacant for 1 hour before using it for another patient; room can be cleaned using routine cleaning procedures.
9. If the patient is discharged home, advise patient to remain home until all lesions have crusted, which usually takes about 5 days.

Laboratory testing
• VZV-specific nucleic acid detected by polymerase chain reaction (PCR) (preferred); or
• VZV antigen detected by direct fluorescent antibody test; or
• Significant rise in serum anti-VZV immunoglobulin G (IgG) antibody level by any standard serologic assay; or
• Isolation of VZV† from a clinical specimen.
• Laboratory testing cannot differentiate between varicella and herpes zoster because they are both caused by VZV. However, laboratory testing can differentiate wild vs. vaccine-type VZV.

Specimen collection for PCR
• A PCR assay can detect VZV nucleic acid in vesicle
swabs, scabs or lesions.

- For PCR, the ideal specimens include scabs and dry lesion swabs. In cases with neurological symptoms, cerebrospinal fluid can also be tested.
  - Remove several scabs (a glass slide is useful for this purpose) and place in a clean, dry container.
  - Swab basal cells from the unroofed lesion.
  - Place swab in clean, dry container.
  - Swabs submitted for PCR should be sent dry rather than diluted in viral transport media (VTM).

Contact CDPH for more detailed instructions and to request testing. See more lab information in “Resources”.

Varicella exposure

- Varicella exposure can occur from direct contact with or aerosolization of lesion material, or through respiratory aerosols from an infectious person.
- Persons with zoster (shingles) can also transmit VZV, i.e., exposure to a person with shingles can result in varicella in a susceptible person.
- The CDC definition of exposure includes close contact with an infectious person, such as close indoor contact (e.g., in the same room) or face-to-face contact. Experts differ in their opinion about the duration of contact; some suggest 5 minutes and others up to 1 hour. It does not include transitory contact.

Varicella contact investigation

1. Contact staff responsible for infection control immediately.
2. Determine if the patient was masked before or immediately upon entry to facility and immediately placed in an AIIR. If not, an exposure investigation should be conducted (Steps 3-12).
3. Identify all potentially exposed patients, visitors, and staff. If staff were only in shared airspace with the patient while using appropriate respiratory protection (N95 or PAPR) then they are not considered exposed.
4. Check the varicella immunity status of exposed staff.
5. Identify exposed patients and staff who are likely to be unvaccinated or who are at high-risk for severe infection (see definition in “Resources”).

   Consider also identifying all children 12-18 months of age as the first dose of varicella vaccine is recommended between 12-15 months of age.

6. Ascertain whether immunization data are available for exposed patients. If no immunization data are in patient medical records, the California Immunization Registry (CAIR) or the appropriate regional immunization registry may be queried. The local health department and CDPH can help check CAIR if the facility does not have access.

7. Plan for the possibility of a need for rapid serologic testing for varicella immunity (varicella IgG) for high risk contacts whose varicella immune status is not known.

8. Plan for the possibility of a need to obtain VarizIG or intravenous (IV) immune globulin (IG) for high risk susceptible contacts, and/or varicella vaccine as post-exposure prophylaxis (PEP) for low risk susceptible contacts according to recommendations (see: CDPH Varicella Quicksheet in “Resources”).
   - Healthcare facilities typically do not stock VarizIG so it may need to be rapidly ordered (see “Resources” section).
   - Hospital pharmacies typically have IGIV in stock if it is needed.

9. Contact persons at known high-risk of severe disease (see “Resources” section) by phone as soon as possible.

10. Contact the parents of infants 12-18 months of age who are potentially unvaccinated.

11. Determine if the exposed person:
   - Has age-appropriate receipt of vaccination, laboratory evidence of immunity, or laboratory confirmation of prior wild-type disease; or
   - Has a plausible history of varicella or zoster as determined by the healthcare provider interviewing the contact; or has
   - Received one dose of varicella vaccine if infant is 12-18 months of age; or
   - Is immunocompromised (see “Resources”); or
   - Had anyone else with them at the time of the exposure, and whether they are high-risk (see
“Resources”), unvaccinated, or a healthcare worker.

12. Contact all other potentially exposed patients.
   • If the number of patients is manageable, these patients can also be contacted by phone.
   • If the number of patients is too large for phone calls to be practical, a certified letter may be sent, or in some healthcare systems, an email.
   • A CDPH template letter is available upon request.

**Postexposure prophylaxis**

If PEP is indicated, and it is within the time window for the indicated PEP, it is the healthcare facility’s responsibility to arrange for PEP administration. Antiviral PEP for healthy, exposed, susceptible persons is not routinely recommended, however, acyclovir as PEP may be considered for some persons.

**Varicella vaccine**

- Varicella vaccine may be effective in preventing illness or modifying illness severity if given within 3-5 days, after first exposure.
- A second dose of varicella vaccine can be given to patients who have received only one dose:
  - Children <13 years of age can receive second dose ≥3 months after their first dose.
  - People ≥13 can receive second dose ≥4 weeks after their first dose.

**Varicella zoster immune globulin (VariZIG)**

- VariZIG should be administered as soon as possible and within 10 days of first exposure to those groups at high risk for severe infection (see “Resources”).
- If VariZIG is not available within the PEP window, IGIV can be given as an alternative.
- One source of VariZIG is FFF Enterprises in Temecula, California, which can be reached 24/7 at 1-800-843-7477 for rapid ordering.
- VariZIG is not indicated for neonates whose mothers have shingles.

**Hospital inpatient unit exposures**

If exposure occurs in a hospital inpatient unit:

- All exposed patients without evidence of immunity should be discharged as soon as possible.
- For exposed patients without evidence of immunity who cannot be discharged, airborne and contact precautions from day 8 until 21 days after exposure to the index patient are indicated.
- Patients who received VariZIG or IGIV should be isolated until through day 28.

**Exposed healthcare workers (HCWs)**

- HCWs who have received 2 doses of vaccine and who are exposed to VZV should be monitored daily during days 8 through 21 after exposure and should be placed on sick leave immediately if symptoms such as fever, headache, other constitutional symptoms, or any suspicious skin lesions occur.
- HCWs who have received only 1 dose of vaccine and who are exposed to VZV should receive the second dose of single-antigen varicella vaccine, preferably within 3 to 5 days of exposure.
- Immunized HCWs who develop breakthrough infection should be considered infectious until vesicular lesions have crusted or, if they had maculopapular lesions, until no new lesions appear within a 24-hour period.

**Presumptive evidence of immunity**

The criteria below provide evidence of immunity to varicella for the purposes of a healthcare exposure:

- Documentation of age-appropriate varicella vaccination (preschool-aged children: 1 dose; school-aged children, adolescents, and adults: 2 doses); or
- U.S. birth before 1980 (this should not be considered evidence of immunity for healthcare personnel, immunocompromised persons, pregnant women and persons born outside the U.S.); or
- Laboratory evidence of immunity; or
- Prior laboratory confirmation of disease; or
- Healthcare provider diagnosis or verification of a history of varicella or shingles.

**Contacts at high risk of severe varicella infection**

- Hematopoietic stem cell transplant recipients;
Varicella Healthcare Exposure Investigation Quicksheet July 2022

- Immunocompromised persons without evidence of varicella immunity (see definition in below);
- Pregnant women without evidence of varicella immunity;
- Newborn infants whose mothers had onset of chickenpox within 5 days before delivery or within 48 hours after delivery;
- Hospitalized preterm infants (28 weeks or more of gestation) whose mother lacks evidence of immunity against varicella;
- Hospitalized preterm infant less than 28 weeks gestation or birth weight 1000 g or less, regardless of maternal immunity.

**Definition of immunocompromised**

Per CDC and [IDSA guidance](https://www.cdc.gov/varicella/patient-care/immunosuppressed.html), patients with high-level immunosuppression include those:

- with combined primary immunodeficiency disorder (e.g., severe combined immunodeficiency);
- who are receiving cancer chemotherapy;
- on treatment for ALL within and until at least 6 months after completion of immunosuppressive chemotherapy;
- within 2 months after solid organ transplantation;
- who have received a bone marrow transplant, until at least 12 months after finishing all immunosuppressive treatment, or longer in patients who have developed graft-versus-host disease;
- with HIV infection with a CD4 T-lymphocyte count <200 cells/mm³ (age >5 years) and percentage <15 (all ages) (some experts include HIV-infected persons who lack recent confirmation of immunologic status or measles immunity);
- receiving daily corticosteroid therapy with a dose ≥20 mg (or >2 mg/kg/day for patients who weigh <10 kg) of prednisone or equivalent for ≥14 days; and
- receiving certain biologic immune modulators, such as a tumor necrosis factor-alpha (TNF-α) blocker or rituximab.

After hematopoietic stem cell transplantation, duration of high-level immunosuppression is highly variable and depends on type of transplant, type of donor and stem cell source, and post-transplant complications such as graft vs. host disease and their treatments.

**California reporting requirements**

- Persons who were hospitalized or died due to varicella infection.
- Varicella clusters (3-4 cases) and outbreaks (≥5 cases).
- Shingles cases are not reportable.
Management of Exposures to Varicella-Zoster
(From 2021-2024 AAP Red Book)

Significant exposure:
- Household: residing in the same household
- Playmate: face-to-face indoor play ≥5 minutes (some experts use >1 hour)
- Newborn infant
- Hospital:
  - Varicella: In same 2- to 4-bed room or adjacent beds in a large ward, face-to-face contact with an infectious staff member or patient, or visit by a person deemed contagious
  - Zoster: Contact (eg, touching or hugging) with a person with disseminated zoster or with uncovered uncrowned lesions

Does the patient have evidence of immunity to varicella based on one or more of the following:
- Receipt of 2 varicella vaccine doses
- Laboratory evidence of immunity or laboratory confirmation of prior wild-type disease
- Prior diagnosis of varicella or zoster by a healthcare provider
- Verification of history of varicella or zoster by healthcare provider

Healthy person

<12 months of age

No

Within 5 days of exposure

Yes

Within 10 days of exposure

No

Yes

If no prior dose of varicella vaccine received, administer monovalent varicella vaccine (Varivax) unless contraindicated

No prophylaxis

No prophylaxis*

No prophylaxis

IGIV, 400 mg/kg

Varicella Zoster Immune Globulin, intramuscularly, 125 units/10 kg body weight (62.5 units if ≤2 kg), up to a maximum of 625 units (6 vials)

Varicella Zoster Immune Globulin or IGIV is not indicated if the mother has zoster

Hospitalized preterm infant (28 wk or more of gestation) whose mother lacks evidence of immunity against varicella

Hospitalized preterm infant less than 28 wk of gestation or birth weight 1000 g or less regardless of maternal immunity

Immunocompromised child/*

Pregnant woman

Newborn infant whose mother had onset of chickenpox within 5 days before delivery or within 48 hours after delivery; Varicella Zoster Immune Globulin or IGIV is not indicated if the mother has zoster

Phone: (510) 620-3737 • Email: ImmunizationBranch@cdph.ca.gov
**Figure Legend**
IGIV indicates Immune Globulin Intravenous. VariZIG is manufactured by Cangene Corporation (Winnipeg, Canada) and distributed in the United States by FFF Enterprises (Temecula, California; 800-843-7477) and ASD Healthcare (Frisco, Texas; 800-746-6273).

*a* People who receive hematopoietic stem cell transplants should be considered nonimmune regardless of previous history of varicella disease or varicella vaccination in themselves or in their donors.

*b* To verify a history of varicella vaccination in an immunocompromised child, health care providers should inquire about an epidemiologic link to another typical varicella case or to a laboratory confirmed case, or evidence of laboratory confirmation. Immunocompromised children who have neither an epidemiologic link nor laboratory confirmation of varicella should not be considered as having history of disease.

*c* Immunocompromised children include those with congenital or acquired T-lymphocyte immunodeficiency, including leukemia, lymphoma, and other malignant neoplasms affecting the bone marrow or lymphatic system; children receiving immunosuppressive therapy, including ≥2 mg/kg/day of systemic prednisone (or its equivalent) for ≥14 days, and certain biologic response modifiers; all children with human immunodeficiency virus (HIV) infection regardless of CD4+ T-lymphocyte percentage; and all hematopoietic stem cell transplant patients regardless of pretransplant immunity status.

*d* If the exposed person is an adolescent or adult, has chronic illness, or there are other compelling reasons to try to avert varicella, some experts recommend preemptive therapy with oral acyclovir (20 mg/kg per dose, administered 4 times per day, with a maximum daily dose of 3200 mg) or oral valacyclovir (if ≥3 months of age; 20 mg/kg per dose, administered 3 times per day, with a maximum daily dose of 3000 mg) beginning 7 to 10 days after exposure and continuing for 7 days. If the child is ≥12 months of age, age-appropriate vaccination still is recommended for protection against subsequent exposures, but vaccine should not be administered while antiviral therapy is being administered; if the exposure occurred during an outbreak, 2-dose vaccination is recommended for preschool-aged children younger than 4 years for outbreak control.

*e* If 1 prior dose of varicella vaccine has been received, a second dose should be administered at ≥4 years of age. If the exposure occurred during an outbreak, a second dose is recommended for preschool-aged children younger than 4 years for outbreak control if at least 3 months have passed after the first dose.

*f* If VariZIG and IGIV are not available, some experts recommend preemptive therapy with oral acyclovir (20 mg/kg per dose, administered 4 times per day, with a maximum daily dose of 3200 mg) or oral valacyclovir (if ≥3 months of age; 20 mg/kg per dose, administered 3 times per day, with a maximum daily dose of 3000 mg) beginning 7 to 10 days after exposure and continuing for 7 days. Preemptive oral acyclovir has only been studied in the normal host but sometimes is used in addition to VariZIG or IGIV in the immunocompromised host.

**Resources**
- [Local health department contacts](https://www.cdph.ca.gov/Programs/CCLHO/CDPH%20Document%20Library/LHD_CD_Contact_Info_ADA.pdf)
- [CDPH Varicella Quicksheet](https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/Varicella-Quicksheet.pdf)
- [CDC/HICPAC Guidelines for Environmental Infection Control in Health-Care Facilities](https://www.cdc.gov/vaccines/pubs/surv-manual/chpt17-varicella.html)
affecting patient care in hospitals and outpatient facilities
(https://www.cdc.gov/infectioncontrol/pdf/guidelines/environmental-guidelines-P.pdf)
• Lab specimen collection
(https://www.cdc.gov/chickenpox/lab-testing/collection-specimens.html)
• Information on VariZIG and IGIV administration is available at:
  o AAP Redbook varicella chapter (above)
  o Updated recommendations for the use of VariZIG – United States, 2013
    (https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6228a4.htm)
• CDC Prevention of Varicella Recommendations of the Advisory Committee on Immunization Practices